* New data in crohn's disease patients shows similar efficacy and safety profiles for inflectra® and remicade®a

* Pfizer inc - further results on longer-term safety and efficacy of inflectra from ongoing 54-week study in cd are expected later this year Source text for Eikon: Further company coverage: